Skip to main content
MenuSearch & Directory

Clinical Trials

Healthy volunteers of all ages, races and genders are needed to continue vaccine development at the Saint Louis University Center for Vaccine Development.

Participation in a vaccine study is voluntary and confidential. All study vaccines and tests are free of charge, and volunteers receive compensation for time and travel. Participation involves completing a short online survey that includes some personal questions. Your participation is voluntary.

Current Studies

Mpox Adolescent Vaccine Study (12-17 years old)

Background 

This is a study of a vaccine approved by the U.S. Food and Drug Administration (FDA) for adults to prevent monkeypox, now called mpox. This study vaccine is not approved by the FDA to be used in kids in the 12-17 age range. The study vaccine is given as a shot (an injection) into the fat of the participant's upper arm. We are testing to see if there are any side effects from the study vaccine. We are also seeing whether the cells in the body that protect against infection and disease will respond to the study vaccine.

Purpose

This research aims to compare the safety and immune response of adolescents and adults receiving the JYNNEOS (MVA-BN) vaccine.

Key Points

  • Participants must be 12-17 years old to participate in the trial. 
  • Participants will be compensated for completed visits.
  • The study lasts about 13 months. 
Mpox Adult Vaccine Study (18-50 years old)

Background

JYNNEOS is a Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine with a well-known safety profile in adults. In 2019, the U.S. Food and Drug Administration (FDA) approved the use of two (0.5 mL) doses of JYNNEOS given subcutaneously (SC) four weeks apart for the prevention of mpox and smallpox in adults. This study will examine the safety and immune response of adolescents compared to adults receiving the licensed dose of JYNNEOS, and give study data to support the FDA approval of JYNNEOS for use in adolescents. The use of this vaccine in this study is investigational as it is not approved by the FDA to be used in adolescents. 

Purpose

This research aims to compare the safety and immune response of adolescents and adults receiving the JYNNEOS (MVA-BN) vaccine.

Key Points

  • Participants must be 18-50 years old to participate.
  • Participants will be compensated for completed visits.
  • The study will last about 13 months.